Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ly-2584702. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 known ✓ | P23443 | 20/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 1.00 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 1.00 |
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 1.00 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 1.00 |
| ▸ | AKT1 | P31749 | 11/20 | 0.65 |
| ▸ | AKT2 | P31751 | 4/20 | 0.60 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ly-2584702 SCHEMBL311653 | 1.00 | RPS6KB1 (1.00) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| Ly-2584702 SCHEMBL311369 | 0.91 | RPS6KB1 (1.00) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| Ly-2584702 SCHEMBL29493101 | 0.91 | RPS6KB1 (1.00) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| Ly-2584702 SCHEMBL312564 | 0.90 | RPS6KB1 (1.00) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| SCHEMBL803893 | 0.85 | RPS6KB1 (0.85) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| Hydrochloric Acid SCHEMBL15732561 | 0.82 | RPS6KB1 (0.83) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| SCHEMBL311654 | 0.81 | RPS6KB1 (0.67) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| Hydrochloric Acid SCHEMBL15732666 | 0.80 | RPS6KB1 (0.79) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| Hydrochloric Acid SCHEMBL15732485 | 0.80 | RPS6KB1 (0.79) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| SCHEMBL3726131 | 0.79 | RPS6KB1 (0.77) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228552-A9 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIVERSITY OF MASSACHUSETTS | 2024-07-11 | — | — | US | claimed |
| CN-118236492-A | Pigmentation inhibition method via inhibition of signal transduction of mTOR signaling pathway | 株式会社资生堂 | 2024-06-25 | — | — | CN | claimed |
| US-20240132551-A1 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIV MASSACHUSETTS (US) | 2024-04-25 | — | — | US | claimed |
| US-12636370-B2 | Combination therapy for treatment of cancer | INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4640682-A2 | COMPOSITIONS OF AGPAT4 INHIBITORS AND METHODS OF USING THEREOF TO TREAT CANCER | The University Of Hong Kong (CN) | 2025-10-29 | — | — | EP | disclosed |
| US-20250243203-A1 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | PURDUE RESEARCH FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| EP-4504174-A2 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | Purdue Research Foundation (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20250041303-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2025-02-06 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| US-11759445-B2 | Use of Rivastigmine in preparation of anti-radiation medicament | SOOCHOW UNIVERSITY (CN) | 2023-09-19 | — | — | US | disclosed |
| WO-2023102379-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2023-06-08 | — | — | WO | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| US-11578130-B2 | Regulatable chimeric antigen receptor | NOVARTIS AG (CH) | 2023-02-14 | — | — | US | disclosed |
| US-20230026049-A1 | REGULATABLE CHIMERIC ANTIGEN RECEPTOR | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230011378-A1 | Combination Therapy For Treatment Of Cancer | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2023-01-12 | — | — | US | disclosed |
| EP-4010081-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20220175714-A1 | USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENT | SOOCHOW UNIVERSITY (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578130-B2 | Regulatable chimeric antigen receptor | CD74, HAVCR2, FCGR2A | RPS6KB1 2151/4885RPS6KA5 3037/4885RPS6KA4 2501/4885 |
| US-12636370-B2 | Combination therapy for treatment of cancer | RB1, MDM2, PHKB | RPS6KB1 160/4885RPS6KA5 356/4885RPS6KA4 511/4885 |
| US-20230011378-A1 | Combination Therapy For Treatment Of Cancer | CDK9, KRAS, BRD9 | RPS6KB1 351/4885RPS6KA5 404/4885RPS6KA4 500/4885 |
| US-20250243203-A1 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | NADK, NAMPT, NNMT | RPS6KB1 530/4885RPS6KA5 492/4885RPS6KA4 515/4885 |
| US-20230026049-A1 | REGULATABLE CHIMERIC ANTIGEN RECEPTOR | CD74, HAVCR2, FCGR2A | RPS6KB1 2151/4885RPS6KA5 3037/4885RPS6KA4 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.